Annual Financials for Tiziana Life Sciences Ltd.
Operating Activities
Fiscal year is January-December. All values USD millions. |
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
Net Income before Extraordinaries |
(9.88M) | (10.01M) | (28.3M) | (26.66M) | (15.4M) | |
Net Income Growth |
- | -1.32% | -182.71% | 5.80% | 42.24% | |
Depreciation, Depletion & Amortization |
16,001 | 252,596 | 91,047 | 141,000 | 51,000 | |
Depreciation and Depletion |
16,001 | 252,596 | 91,047 | 141,000 | 51,000 | |
Amortization of Intangible Assets |
- | - | - | - | - | |
Deferred Taxes & Investment Tax Credit |
- | - | - | - | - | |
Deferred Taxes |
- | - | - | - | - | |
Investment Tax Credit |
- | - | - | - | - | |
Other Funds |
3.32M | 2.68M | 16.58M | 5.53M | (3.11M) | |
Funds from Operations |
(6.54M) | (7.08M) | (11.63M) | (20.99M) | (18.45M) | |
Extraordinaries |
- | - | - | - | - | |
Changes in Working Capital |
1.94M | 287,041 | (293,659) | (773,000) | (1.16M) | |
Receivables |
(180,010) | (127,574) | (466,777) | 428,000 | (156,000) | |
Accounts Payable |
- | - | - | - | - | |
Other Assets/Liabilities |
2.12M | 414,615 | 173,118 | (1.2M) | (1.01M) | |
Net Operating Cash Flow |
(4.6M) | (6.79M) | (11.92M) | (21.76M) | (19.62M) | |
Net Operating Cash Flow Growth |
- | -47.63% | -75.50% | -82.54% | 9.87% | |
Net Operating Cash Flow / Sales |
- | - | - | - | - | |
Investing Activities
|
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
Capital Expenditures |
- | (3,827) | (126,953) | (22,000) | - | |
Capital Expenditures (Fixed Assets) |
- | (3,827) | (2,565) | (22,000) | - | |
Capital Expenditures (Other Assets) |
- | - | (124,388) | - | - | |
Capital Expenditures Growth |
- | - | -3,217.30% | 82.67% | - | |
Capital Expenditures / Sales |
- | - | - | - | - | |
Net Assets from Acquisitions |
- | - | - | - | - | |
Sale of Fixed Assets & Businesses |
- | - | - | - | - | |
Purchase/Sale of Investments |
- | - | - | - | (2.68M) | |
Purchase of Investments |
- | - | - | - | (2.68M) | |
Sale/Maturity of Investments |
- | - | - | - | - | |
Other Uses |
- | - | - | - | (1.32M) | |
Other Sources |
- | - | - | 152,000 | - | |
Net Investing Cash Flow |
- | (3,827) | (126,953) | 130,000 | (4M) | |
Net Investing Cash Flow Growth |
- | - | -3,217.30% | 202.40% | -3,173.85% | |
Net Investing Cash Flow / Sales |
- | - | - | - | - | |
Financing Activities
|
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
Cash Dividends Paid - Total |
- | - | - | - | - | |
Common Dividends |
- | - | - | - | - | |
Preferred Dividends |
- | - | - | - | - | |
Change in Capital Stock |
10.09M | 1.88M | 73.96M | 129,000 | - | |
Repurchase of Common & Preferred Stk. |
- | - | - | - | - | |
Sale of Common & Preferred Stock |
10.09M | 1.88M | 73.96M | 129,000 | - | |
Proceeds from Stock Options |
8.58M | - | 69.44M | - | - | |
Other Proceeds from Sale of Stock |
1.51M | 1.88M | 4.53M | 129,000 | - | |
Issuance/Reduction of Debt, Net |
- | - | - | - | - | |
Change in Current Debt |
- | - | - | - | - | |
Change in Long-Term Debt |
- | - | - | - | - | |
Issuance of Long-Term Debt |
- | - | - | - | - | |
Reduction in Long-Term Debt |
- | - | - | - | - | |
Other Funds |
- | - | - | - | - | |
Other Uses |
- | - | - | - | - | |
Other Sources |
- | - | - | - | - | |
Net Financing Cash Flow |
10.09M | 1.68M | 73.68M | (23,000) | (55,000) | |
Net Financing Cash Flow Growth |
- | -83.36% | 4,288.90% | -100.03% | -139.13% | |
Net Financing Cash Flow / Sales |
- | - | - | - | - | |
Exchange Rate Effect |
- | - | - | (1.98M) | (398,000) | |
Miscellaneous Funds |
- | - | - | - | - | |
Net Change in Cash |
5.49M | (5.12M) | 61.64M | (23.64M) | (24.06M) | |
Free Cash Flow |
(4.6M) | (6.8M) | (11.92M) | (21.78M) | (19.62M) | |
Free Cash Flow Growth |
- | -47.71% | -75.44% | -82.68% | 9.96% | |
Free Cash Flow Yield |
- | - | - | - | -32.28% | NA |